Latest News-BUCHAN CONSULTING PTY LTD Mediaroom_Page

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

* The data provides further validation of the intended Phase 2 study design MELBOURNE, Australia ...

2022-04-07 09:34 1867

Alterity Therapeutics to Present at the 34th Annual Roth Conference

MELBOURNE, Australia and SAN FRANCISCO, March 7, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: A...

2022-03-07 20:59 1805

Prota Therapeutics Achieves Peanut Allergy Treatment Milestone: Groundbreaking Clinical Trial Data Demonstrates Clinical Remission of Peanut Allergy in Paediatric Patients

* Groundbreaking New Clinical Trial Data Published in The Lancet Child & Adolescent Health * Da...

2022-02-09 20:00 1395

Alterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease

MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...

2022-01-28 20:08 2037

Appendix 4C - Q2 FY22 Quarterly Cash Flow Report

Highlights: * NZ's regulator Medsafe authorizes Phase 2 clinical trial for ATH434; more jurisdic...

2022-01-27 20:45 4773

Trajan Group acquires Neoteryx LLC

MELBOURNE, Australia, Jan. 10, 2022 /PRNewswire/ -- Global analytical science and device company Tr...

2022-01-11 00:00 2340

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: AT...

2022-01-06 20:30 3166

Alterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

MELBOURNE, Australia, Jan. 5, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (...

2022-01-05 20:45 3173

Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

MELBOURNE, Australia, Dec. 14, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ...

2021-12-14 20:25 1668

Trajan to acquire LEAP PAL Parts

MELBOURNE, Australia, Dec. 9, 2021 /PRNewswire/ -- Global analytical science and device company Tra...

2021-12-09 21:00 1855

Trajan Group acquires Axel Semrau GmbH

MELBOURNE, Australia, Nov. 22, 2021 /PRNewswire/ -- Global analytical science and device company Tr...

2021-11-22 23:30 1924

Alterity Therapeutics to Participate in Two Upcoming Investor Conferences

MELBOURNE, Australia and SAN FRANCISCO, Nov. 22, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: A...

2021-11-22 20:50 1812

Investment Confidence in Icon Group to Drive Next Phase of Global Growth With EQT Infrastructure Investment

BRISBANE, Australia, Nov. 19, 2021 /PRNewswire/ -- Icon Group has today announced it will enter the...

2021-11-19 09:19 2227

Planet Innovation acquires BIT Group's North American operations, doubling its medtech manufacturing capacity

MELBOURNE, Australia, Nov. 11, 2021 /PRNewswire/ -- Planet Innovation (PI) has acquired the North A...

2021-11-12 07:44 1908

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

MELBOURNE, Australia, Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (...

2021-11-09 20:30 1431

Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases

MELBOURNE, Australia, Nov. 5, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (...

2021-11-05 14:57 1530

Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases

MELBOURNE, Australia, Nov. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (...

2021-11-04 19:30 1453

Appendix 4C - Q1 FY22 Quarterly Cash Flow Report

Highlights: * New details on ATH34 Phase 2 clinical trial released. * Data from bioMUSE present...

2021-10-29 14:50 2172

Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program

- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding ...

2021-10-20 05:08 1655

Alterity Announces Presentation of Biomarker Data at the International Parkinson and Movement Disorder Society Congress 2021

MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ...

2021-09-20 22:51 6820